| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
MAP4343 targets microtubule-associated protein 2 (MAP2). MAP2 is a protein that binds to microtubules and stabilizes them, playing a critical role in neuronal development and plasticity. By binding to MAP2, MAP4343 stimulates the polymerization of tubulin, which is the building block of microtubules. This leads to enhanced neurite extension and neuroprotection.
|
|---|---|
| ln Vitro |
In vitro, microtubule polymerization is stimulated by MAP4343 (40 μM; 15 or 30 min)[1]. In PC12 cells, MAP4343 (30 μM; 2–8 d) increases neurite outgrowth induced by nerve growth factor (NGF)[1]. In PC12 cells, MAP4343 (20 μM; 1 h) guards against microtubule depolymerization brought on by nocodazole[1].
In vitro, MAP4343 binds to microtubule-associated protein 2 (MAP2) and stimulates the polymerization of tubulin. This results in enhanced neurite extension and protection of neurons from neurotoxic agents. These in vitro activities support its use in studying neuroprotection, neurite outgrowth, and neuronal function. |
| ln Vivo |
Rats with spinal cord injury (SCI) recover more quickly after taking MAP4343 (12 mg/kg; sc daily for 28 days)[2]. After SCI in rats, MAP4343 (4 mg/kg; daily SC for 6 days) raises MAP2 levels in the spinal cord[2]. After SCI in rats, MAP4343 (4 mg/kg; daily sc for 6 d) increases the size of the dendritic arbours of lumbar spinal motoneurons[2].
In vivo, MAP4343 has shown promise in preclinical studies for reducing depressive-like behaviors, supporting cognitive function, and protecting against neuroinflammatory damage. It is a synthetic derivative of the neurosteroid pregnenolone, designed to enhance neuroprotective and antidepressant properties without hormonal side effects. However, specific published in vivo efficacy studies are not detailed in the current literature. |
| Enzyme Assay |
The in vitro MAP2 binding assay for MAP4343 is conducted using purified MAP2 protein. The compound's binding affinity is measured using techniques such as surface plasmon resonance or fluorescence polarization. Tubulin polymerization is assessed by measuring the increase in turbidity over time in the presence of tubulin and varying concentrations of MAP4343. Neurite outgrowth is assessed in neuronal cell cultures.
|
| Cell Assay |
Cellular assays for MAP4343 are conducted in neuronal cell lines or primary neurons. Cells are treated with varying concentrations of MAP4343. Neurite outgrowth is quantified by microscopy. Neuroprotection is assessed by measuring cell viability after exposure to neurotoxic agents. The compound's effects on microtubule dynamics are assessed by immunostaining for tubulin.
|
| Animal Protocol |
Animal/Disease Models: Adult SD (Sprague-Dawley) male rats with spinal cord injury[2]
Doses: 12 mg/kg Route of Administration: Daily sc for 28 days Experimental Results: Increased the number of animals able to walk with weight-supported plantar steps. demonstrated forelimb-hindlimb coordination at the end of the study. In vivo studies for MAP4343 are conducted in animal models of depression, cognitive impairment, or neuroinflammation. The compound is administered via oral or intraperitoneal routes. Efficacy is assessed by measuring behavioral outcomes, cognitive function, and neuroinflammatory markers. However, specific published in vivo protocols for MAP4343 are not available in the current literature. |
| ADME/Pharmacokinetics |
MAP4343 has a molecular weight of 330.50 and a molecular formula of C22H34O2. It has a CAS number of 511-26-2. As a small molecule, it is expected to have good oral bioavailability. Detailed PK parameters such as half-life and bioavailability are not extensively reported in the provided sources.
|
| Toxicity/Toxicokinetics |
Toxicity data for MAP4343 is limited. As a derivative of pregnenolone, it is expected to have a favorable safety profile. However, as with all research compounds, MAP4343 is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment.
|
| References | |
| Additional Infomation |
MAP4343 (CAS 511-26-2) is the 3-methylether derivative of Pregnenolone. It binds to MAP2 and stimulates tubulin polymerization, enhancing neurite extension and neuroprotection. It has shown promise in preclinical studies for reducing depressive-like behaviors. It has a molecular formula of C22H34O2 and a molecular weight of 330.50. It is for research use only.
|
| Molecular Formula |
C22H34O2
|
|---|---|
| Molecular Weight |
330.50
|
| Exact Mass |
330.256
|
| CAS # |
511-26-2
|
| Related CAS # |
MAP4343-d4
|
| PubChem CID |
233254
|
| Appearance |
White to off-white solid powder
|
| Density |
1.04g/cm3
|
| Boiling Point |
426.6ºC at 760mmHg
|
| Flash Point |
161.3ºC
|
| Index of Refraction |
1.529
|
| LogP |
5.169
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
564
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC)C)C
|
| InChi Key |
ZVGQOQHAMHMMNE-BIBIXIOVSA-N
|
| InChi Code |
InChI=1S/C22H34O2/c1-14(23)18-7-8-19-17-6-5-15-13-16(24-4)9-11-21(15,2)20(17)10-12-22(18,19)3/h5,16-20H,6-13H2,1-4H3/t16-,17-,18+,19-,20-,21-,22+/m0/s1
|
| Chemical Name |
1-[(3S,8S,9S,10R,13S,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 25 mg/mL (75.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.56 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0257 mL | 15.1286 mL | 30.2572 mL | |
| 5 mM | 0.6051 mL | 3.0257 mL | 6.0514 mL | |
| 10 mM | 0.3026 mL | 1.5129 mL | 3.0257 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
